-
1
-
-
79953065066
-
A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
-
Barrington P, Chien JY, Showalter HDH, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(5):426–433.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.5
, pp. 426-433
-
-
Barrington, P.1
Chien, J.Y.2
Showalter, H.D.H.3
-
2
-
-
84940022669
-
A novel, long-acting glucagon-like peptide receptor-agonist: Dulaglutide
-
Gurung T, Shyangdan DS, O’Hare JP, Waugh N. A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide. Diabetes Metab Syndr Obes. 2015;8:363–386.
-
(2015)
Diabetes Metab Syndr Obes
, vol.8
, pp. 363-386
-
-
Gurung, T.1
Shyangdan, D.S.2
O’Hare, J.P.3
Waugh, N.4
-
3
-
-
84969988486
-
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: A comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
-
Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016;32(8):776–790.
-
(2016)
Diabetes Metab Res Rev
, vol.32
, Issue.8
, pp. 776-790
-
-
Jendle, J.1
Grunberger, G.2
Blevins, T.3
Giorgino, F.4
Hietpas, R.T.5
Botros, F.T.6
-
4
-
-
84968867240
-
Advances in the treatment of type 2 diabetes: Impact of dulaglutide
-
Thompson AM, Trujillo JM. Advances in the treatment of type 2 diabetes: impact of dulaglutide. Diabetes Metab Syndr Obes. 2016;9:125–136.
-
(2016)
Diabetes Metab Syndr Obes
, vol.9
, pp. 125-136
-
-
Thompson, A.M.1
Trujillo, J.M.2
-
5
-
-
85014514372
-
Dulaglutide for the treatment of type 2 diabetes
-
Scheen AJ. Dulaglutide for the treatment of type 2 diabetes. Expert Opin Biol Ther. 2017;17(4):485–496.
-
(2017)
Expert Opin Biol Ther
, vol.17
, Issue.4
, pp. 485-496
-
-
Scheen, A.J.1
-
6
-
-
85050209004
-
-
Trulicity (dulaglutide) injection, solution [prescribing information] Indianapolis, IN: Eli Lilly and Company; 2017.
-
(2017)
Eli Lilly and Company
-
-
-
8
-
-
84904360390
-
Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)
-
Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37(8):2168–2176.
-
(2014)
Diabetes Care
, vol.37
, Issue.8
, pp. 2168-2176
-
-
Umpierrez, G.1
Tofe Povedano, S.2
Perez Manghi, F.3
Shurzinske, L.4
Pechtner, V.5
-
9
-
-
84939565260
-
Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): A randomized, phase III study
-
Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17(9):849–858.
-
(2015)
Diabetes Obes Metab
, vol.17
, Issue.9
, pp. 849-858
-
-
Weinstock, R.S.1
Guerci, B.2
Umpierrez, G.3
Nauck, M.A.4
Skrivanek, Z.5
Milicevic, Z.6
-
10
-
-
84952014744
-
A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: An open-label, nonrandomized, phase 3 trial
-
Emoto M, Terauchi Y, Ozeki A, Oura T, Takeuchi M, Imaoka T. A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial. Endocr J. 2015;62(12):1101–1114.
-
(2015)
Endocr J
, vol.62
, Issue.12
, pp. 1101-1114
-
-
Emoto, M.1
Terauchi, Y.2
Ozeki, A.3
Oura, T.4
Takeuchi, M.5
Imaoka, T.6
-
11
-
-
84905012167
-
Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)
-
Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159–2167.
-
(2014)
Diabetes Care
, vol.37
, Issue.8
, pp. 2159-2167
-
-
Wysham, C.1
Blevins, T.2
Arakaki, R.3
-
12
-
-
84908177336
-
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): A randomised, open-label, phase 3, non-inferiority trial
-
Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349–1357.
-
(2014)
Lancet
, vol.384
, Issue.9951
, pp. 1349-1357
-
-
Dungan, K.M.1
Povedano, S.T.2
Forst, T.3
-
13
-
-
84957851776
-
Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study
-
Odawara M, Miyagawa J, Iwamoto N, Takita Y, Imaoka T, Takamura T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Diabetes Obes Metab. 2016;18(3):249–257.
-
(2016)
Diabetes Obes Metab
, vol.18
, Issue.3
, pp. 249-257
-
-
Odawara, M.1
Miyagawa, J.2
Iwamoto, N.3
Takita, Y.4
Imaoka, T.5
Takamura, T.6
-
14
-
-
84962338740
-
Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)
-
Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38(12):2241–2249.
-
(2015)
Diabetes Care
, vol.38
, Issue.12
, pp. 2241-2249
-
-
Giorgino, F.1
Benroubi, M.2
Sun, J.H.3
Zimmermann, A.G.4
Pechtner, V.5
-
15
-
-
84930074468
-
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): A randomised, open-label, phase 3, non-inferiority study
-
Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385(9982):2057–2066.
-
(2015)
Lancet
, vol.385
, Issue.9982
, pp. 2057-2066
-
-
Blonde, L.1
Jendle, J.2
Gross, J.3
-
16
-
-
84942256934
-
Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: A randomized, open-label, phase III, non-inferiority study
-
Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, Imaoka T. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes Obes Metab. 2015;17(10):994–1002.
-
(2015)
Diabetes Obes Metab
, vol.17
, Issue.10
, pp. 994-1002
-
-
Araki, E.1
Inagaki, N.2
Tanizawa, Y.3
Oura, T.4
Takeuchi, M.5
Imaoka, T.6
-
17
-
-
85017656003
-
Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)
-
Pozzilli P, Norwood P, Jodar E, et al. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017;19(7):1024–1031.
-
(2017)
Diabetes Obes Metab
, vol.19
, Issue.7
, pp. 1024-1031
-
-
Pozzilli, P.1
Norwood, P.2
Jodar, E.3
-
18
-
-
84975720736
-
A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8)
-
Dungan KM, Weitgasser R, Perez Manghi F, et al. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes Metab. 2016;18(5):475–482.
-
(2016)
Diabetes Obes Metab
, vol.18
, Issue.5
, pp. 475-482
-
-
Dungan, K.M.1
Weitgasser, R.2
Perez Manghi, F.3
-
19
-
-
85019155331
-
Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials
-
Monami M, Zannoni S, Pala L, et al. Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Int J Cardiol. 2017;240:414–421.
-
(2017)
Int J Cardiol
, vol.240
, pp. 414-421
-
-
Monami, M.1
Zannoni, S.2
Pala, L.3
-
20
-
-
84959155948
-
Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: A pre-specified meta-analysis of prospectively adjudicated cardiovascular events
-
Ferdinand KC, Botros FT, Atisso CM, Sager PT. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2016;15(1):38.
-
(2016)
Cardiovasc Diabetol
, vol.15
, Issue.1
, pp. 38
-
-
Ferdinand, K.C.1
Botros, F.T.2
Atisso, C.M.3
Sager, P.T.4
-
21
-
-
85046561203
-
-
Bethesda, MD: National Library of Medicine; 2011–2013: clinicaltrials.gov. NLM Identifier: NCT01394952. Accessed March 22
-
Eli Lilly and Company. Researching cardiovascular events with a weekly incretin in diabetes (REWIND). Bethesda, MD: National Library of Medicine; 2011–2013. Available from: clinicaltrials.gov. NLM Identifier: NCT01394952. Accessed March 22, 2018.
-
(2018)
Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND).
-
-
-
22
-
-
84943197778
-
Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
-
Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26–37.
-
(2015)
Diabetes Res Clin Pract
, vol.110
, Issue.1
, pp. 26-37
-
-
Sun, F.1
Wu, S.2
Guo, S.3
-
23
-
-
84914666192
-
Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus
-
Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64(4):731–737.
-
(2014)
Hypertension
, vol.64
, Issue.4
, pp. 731-737
-
-
Ferdinand, K.C.1
White, W.B.2
Calhoun, D.A.3
-
24
-
-
85014807800
-
Efficacy and safety of dulaglutide in Hispanic/Latino patients with type 2 diabetes in the AWARD clinical program
-
Davidson JA, Manghi FP, Yu M, Linetzky B, Lando LF. Efficacy and safety of dulaglutide in Hispanic/Latino patients with type 2 diabetes in the AWARD clinical program. Endocr Pract. 2016;22(12):1406–1414.
-
(2016)
Endocr Pract
, vol.22
, Issue.12
, pp. 1406-1414
-
-
Davidson, J.A.1
Manghi, F.P.2
Yu, M.3
Linetzky, B.4
Lando, L.F.5
-
25
-
-
85018340448
-
Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment
-
Hamano K, Nishiyama H, Matsui A, Sato M, Takeuchi M. Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment. Endocr J. 2017;64(4):449–456.
-
(2017)
Endocr J
, vol.64
, Issue.4
, pp. 449-456
-
-
Hamano, K.1
Nishiyama, H.2
Matsui, A.3
Sato, M.4
Takeuchi, M.5
-
26
-
-
85020089476
-
Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan
-
Onishi Y, Oura T, Matsui A, Matsuura J, Iwamoto N. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan. Endocr J. 2017;64(5):553–560.
-
(2017)
Endocr J
, vol.64
, Issue.5
, pp. 553-560
-
-
Onishi, Y.1
Oura, T.2
Matsui, A.3
Matsuura, J.4
Iwamoto, N.5
-
27
-
-
84953898275
-
Efficacy and safety of dulaglutide in patients with type 2 diabetes: A meta-analysis and systematic review
-
Zhang L, Zhang M, Zhang Y, Tong N. Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Sci Rep. 2016;6:18904.
-
(2016)
Sci Rep
, vol.6
-
-
Zhang, L.1
Zhang, M.2
Zhang, Y.3
Tong, N.4
-
28
-
-
84962028683
-
Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes
-
Onishi Y, Oura T, Nishiyama H, Ohyama S, Takeuchi M, Iwamoto N. Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes. Endocr J. 2016;63(3):263–273.
-
(2016)
Endocr J
, vol.63
, Issue.3
, pp. 263-273
-
-
Onishi, Y.1
Oura, T.2
Nishiyama, H.3
Ohyama, S.4
Takeuchi, M.5
Iwamoto, N.6
-
29
-
-
84955304504
-
Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: A systematic review and network meta-analysis
-
Zaccardi F, Htike ZZ, Webb DR, Khunti K, Davies MJ. Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis. Ann Intern Med. 2016;164(2):102–113.
-
(2016)
Ann Intern Med
, vol.164
, Issue.2
, pp. 102-113
-
-
Zaccardi, F.1
Htike, Z.Z.2
Webb, D.R.3
Khunti, K.4
Davies, M.J.5
-
30
-
-
85019350081
-
Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide
-
Nauck MA, Frossard JL, Barkin JS, et al. Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide. Diabetes Care. 2017;40(5):647–654.
-
(2017)
Diabetes Care
, vol.40
, Issue.5
, pp. 647-654
-
-
Nauck, M.A.1
Frossard, J.L.2
Barkin, J.S.3
-
31
-
-
85014039439
-
Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials
-
Emoto M, Oura T, Matsui A, Kazama H, Iwamoto N. Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials. Endocr J. 2017;64(2): 191–206.
-
(2017)
Endocr J
, vol.64
, Issue.2
, pp. 191-206
-
-
Emoto, M.1
Oura, T.2
Matsui, A.3
Kazama, H.4
Iwamoto, N.5
-
32
-
-
84961174431
-
Tumour risk with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review
-
Guo X, Yang Q, Dong J, Liao L, Zhang W, Liu F. Tumour risk with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: a systematic review. Clin Drug Investig. 2016;36(6):433–441.
-
(2016)
Clin Drug Investig
, vol.36
, Issue.6
, pp. 433-441
-
-
Guo, X.1
Yang, Q.2
Dong, J.3
Liao, L.4
Zhang, W.5
Liu, F.6
-
33
-
-
85007008175
-
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
-
Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336–347.
-
(2017)
Diabetes Obes Metab
, vol.19
, Issue.3
, pp. 336-347
-
-
Bettge, K.1
Kahle, M.2
Abd El Aziz, M.S.3
Meier, J.J.4
Nauck, M.A.5
-
34
-
-
85026922718
-
Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A meta-analysis of randomized controlled trials
-
Dicembrini I, Nreu B, Scatena A, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54(10):933–941.
-
(2017)
Acta Diabetol
, vol.54
, Issue.10
, pp. 933-941
-
-
Dicembrini, I.1
Nreu, B.2
Scatena, A.3
-
35
-
-
85038423099
-
Liraglutide and renal outcomes in type 2 diabetes
-
Mann JFE, Orsted DD, Buse JB. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(22):2197–2198.
-
(2017)
N Engl J Med
, vol.377
, Issue.22
, pp. 2197-2198
-
-
Mann, J.F.E.1
Orsted, D.D.2
Buse, J.B.3
-
36
-
-
84958767889
-
Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide
-
Grunberger G, Forst T, Fernandez Lando L, et al. Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide. Diabet Med. 2016;33(3):391–394.
-
(2016)
Diabet Med
, vol.33
, Issue.3
, pp. 391-394
-
-
Grunberger, G.1
Forst, T.2
Fernandez Lando, L.3
-
37
-
-
84979285154
-
Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes
-
Wysham C, Guerci B, D’Alessio D, Jia N, Botros FT. Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(11): 1138–1142.
-
(2016)
Diabetes Obes Metab
, vol.18
, Issue.11
, pp. 1138-1142
-
-
Wysham, C.1
Guerci, B.2
D’Alessio, D.3
Jia, N.4
Botros, F.T.5
-
38
-
-
84939478562
-
Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: Data from the AWARD-1 and AWARD-3 clinical trials
-
Reaney M, Yu M, Lakshmanan M, Pechtner V, van Brunt K. Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes Obes Metab. 2015;17(9):896–903.
-
(2015)
Diabetes Obes Metab
, vol.17
, Issue.9
, pp. 896-903
-
-
Reaney, M.1
Yu, M.2
Lakshmanan, M.3
Pechtner, V.4
van Brunt, K.5
-
39
-
-
84959871701
-
Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: Data from the AWARD phase III clinical trial programme
-
Yu M, Van Brunt K, Varnado OJ, Boye KS. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016;18(4):419–424.
-
(2016)
Diabetes Obes Metab
, vol.18
, Issue.4
, pp. 419-424
-
-
Yu, M.1
van Brunt, K.2
Varnado, O.J.3
Boye, K.S.4
-
40
-
-
85020393265
-
Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: Comparisons with liraglutide, insulin glargine, and placebo in two randomized studies
-
Suzuki S, Oura T, Takeuchi M, Boye KS. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies. Health Qual Life Outcomes. 2017;15(1):123.
-
(2017)
Health Qual Life Outcomes
, vol.15
, Issue.1
, pp. 123
-
-
Suzuki, S.1
Oura, T.2
Takeuchi, M.3
Boye, K.S.4
-
41
-
-
85039705599
-
Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes – 2018
-
American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes – 2018. Diabetes Care. 2018;41(suppl 1):S73–S85.
-
(2018)
Diabetes Care.
, vol.41
, pp. S73-S85
-
-
-
42
-
-
84978839381
-
Liraglutide and cardiovascular outcomes in type 2 diabetes
-
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
-
(2016)
N Engl J Med
, vol.375
, Issue.4
, pp. 311-322
-
-
Marso, S.P.1
Daniels, G.H.2
Brown-Frandsen, K.3
-
43
-
-
84994813253
-
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
-
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19): 1834–1844.
-
(2016)
N Engl J Med
, vol.375
, Issue.19
, pp. 1834-1844
-
-
Marso, S.P.1
Bain, S.C.2
Consoli, A.3
-
44
-
-
85030448557
-
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
-
Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13): 1228–1239.
-
(2017)
N Engl J Med
, vol.377
, Issue.13
, pp. 1228-1239
-
-
Holman, R.R.1
Bethel, M.A.2
Mentz, R.J.3
-
45
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22): 2117–2128.
-
(2015)
N Engl J Med
, vol.373
, Issue.22
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
-
46
-
-
85034774651
-
Canagliflozin and cardiovascular and renal events in type 2 diabetes
-
Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(21):644–657.
-
(2017)
N Engl J Med
, vol.377
, Issue.21
, pp. 644-657
-
-
Neal, B.1
Perkovic, V.2
Matthews, D.R.3
|